Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 16/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 14/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | CCR3 | P51677 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3317788 | 1.00 | PIK3CD (0.46) | PIK3CDPIK3CAHRH1CCR3KCNH2 | |
| SCHEMBL13362084 | 0.90 | PDE4B (0.48) | PIK3CDPIK3CAHRH1CCR3KCNH2 | |
| SCHEMBL13362028 | 0.86 | HRH1 (0.46) | PIK3CDPIK3CAHRH1CCR3KCNH2 | |
| SCHEMBL13362079 | 0.85 | OXTR (0.49) | HRH1CCR3KCNH2ALDH1A1CYP3A4 | |
| SCHEMBL15174208 | 0.85 | F10 (0.39) | PIK3CDPIK3CA | |
| SCHEMBL15174207 | 0.83 | PIK3CD (0.41) | PIK3CDPIK3CA | |
| SCHEMBL13362094 | 0.82 | ALDH1A1 (0.47) | PIK3CDPIK3CAHRH1CCR3KCNH2 | |
| SCHEMBL1782598 | 0.82 | ALDH1A1 (0.50) | PIK3CDPIK3CAHRH1CCR3KCNH2 | |
| SCHEMBL1912083 | 0.82 | ALDH1A1 (0.50) | PIK3CDPIK3CAHRH1CCR3KCNH2 | |
| SCHEMBL10208091 | 0.82 | ALDH1A1 (0.50) | PIK3CDPIK3CAHRH1CCR3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010049731-A1 | PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | WO | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | TYMS, ABCG2, UMPS | PIK3CD 935/4885PIK3CA 398/4885HRH1 1145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.